Last edition
News about " Vidofludimus Calcium"
Immunic Secures European Patent for Vidofludimus Calcium, Strengthening Long-Term Market Exclusivity
Immunic receives European patent protection for Vidofludimus Calcium dosing regimens, reinforcing intellectual property coverage and potentially extending exclusivity for the multiple sclerosis therapy in Europe until 2043.
Vidofludimus Calcium | 12/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members